Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Orchid receives FDA OK for divalproex delayed-release tablets

This article was originally published in Scrip

Executive Summary

Orchid Chemicals & Pharmaceuticalshas received approval from the US FDAfor its ANDA for divalproex sodium delayed-release tablets 125mg, 250mg and 500mg, generic versions of Abbott Laboratories' Depakote tablets. Divalproex sodium delayed-release tablets are indicated as monotherapy and adjunctive therapy in the treatment of complex partial seizures, as sole and adjunct therapy for patients with simple and complex absence seizures, for the treatment of the manic episodes associated with bipolar disorders, as well as for prophylaxis of migraine headaches. In July this year, the FDA approved about eight generic versions of Depakote tablets, including those of the Indian companies Sun Pharmaceutical Industries, Lupin and Dr Reddy's Laboratories.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts